Trospium / Xanomeline and Mobocertinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mobocertinib
Trospium / Xanomeline
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking Exkivity (mobocertinib) together with Cobenfy, which contains xanomeline. Your body uses a liver-and-gut enzyme called CYP3A4 to break down mobocertinib. Xanomeline can briefly slow that enzyme down in the gut, so a little more mobocertinib may get into your system than usual.
In practice, that could mean a higher chance of mobocertinib's usual side effects, like diarrhea, nausea, or heart rhythm changes. This is based mostly on how the drugs work in theory, not on strong real-world proof, so I don't want you to worry. Your care team can manage this easily by keeping a closer eye on you and adjusting your dose if needed.
Mechanism: Xanomeline transiently inhibits intestinal CYP3A4 (not systemic). Mobocertinib is a sensitive oral CYP3A4 substrate, so co-administration may increase mobocertinib exposure (AUC/Cmax).
Direction: Increased mobocertinib effect and adverse-reaction risk (GI toxicity, QTc prolongation). Neither agent's active moiety depends on CYP3A4 activation, so this is a straightforward exposure increase.
- Onset: unspecified
- Evidence: theoretical
- Severity: moderate
Management: Monitor for increased frequency/severity of mobocertinib adverse effects; consider ECG/QTc and GI monitoring. Dose may be individualized by the care team if toxicity emerges.
What happens
Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-related adverse reactions
Interaction Deep Dive
Within the gut, xanomeline produces a temporary, local inhibition of CYP3A4, though it does not do so systemically. When xanomeline is taken together with oral medications that are sensitive CYP3A4 substrates, the exposure to those oral sensitive CYP3A4 substrates may rise. As a result, adverse reactions from these substrates could occur more often and/or become more severe. In cases of concurrent administration, watch patients for any increase in the frequency and/or severity of adverse reactions associated with oral drugs that are sensitive substrates of CYP3A41.
Why it happens (mechanism)
Inhibition of CYP3A4-substrate metabolism by xanomeline
How to manage this interaction
Here is how a care team typically handles this combination:
- Keep taking both as prescribed unless your prescriber tells you otherwise.
- Your team may watch you more closely for mobocertinib side effects like diarrhea, nausea, or heart rhythm changes.
- Your mobocertinib dose may be adjusted and individualized by your care team if side effects show up.
Let your pharmacist or doctor know if you notice new or worsening diarrhea, nausea, dizziness, or a fluttering heartbeat. Bring a full medication list to each visit so they can spot combinations like this.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Trospium / Xanomeline and Mobocertinib together?
Cobenfy (xanomeline) can raise levels of mobocertinib by briefly slowing gut CYP3A4, which may increase its side effects; keep taking both as prescribed and let your care team monitor you for symptoms. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Trospium / Xanomeline and Mobocertinib interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Trospium / Xanomeline and Mobocertinib interaction managed?
Here is how a care team typically handles this combination: Keep taking both as prescribed unless your prescriber tells you otherwise. Your team may watch you more closely for mobocertinib side effects like diarrhea, nausea, or heart rhythm changes. Your mobocertinib dose may be adjusted and individualized by your care team if side effects show up. Let your pharmacist or doctor know if you notice… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Trospium / Xanomeline or Mobocertinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Citation #1
Keep reading about Mobocertinib
Keep reading about Trospium / Xanomeline
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist